⌘K

11:09:18·69d

SECFilingvia Quantisnow

Amendment: SEC Form SCHEDULE 13G/A filed by Eupraxia Pharmaceuticals Inc.

ByQuantisnow·Wall Street's wire, on your screen.

EPRX· Eupraxia Pharmaceuticals Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

EPRX
Eupraxia Pharmaceuticals Inc.
Health Care

Recent analyst ratings

Mar 23UpdateWilliam Blair-
Jul 24UpdateCantor Fitzgerald$11.00
Jun 26UpdateH.C. Wainwright$12.00
Jun 16UpdateCanaccord Genuity-
Feb 21UpdateCraig Hallum$12.00
Nov 14UpdateRodman & Renshaw$9.00

Related

SEC5d
SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
PR5d
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
SEC6d
SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
PR6d
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
SEC13d
SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
SEC13d
SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
PR14d
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
ANALYST35d
William Blair initiated coverage on Eupraxia Pharmaceuticals